Genflow Biosciences PLC Announces Holding(s) in Company
Rhea-AI Summary
Genflow Biosciences (OTC:GENFF) disclosure shows Jonathan Mark Swann increased his holding to 11.32% of voting rights in Genflow Biosciences on 23-Oct-2025, up from 8.40% in the prior notification.
The resulting position equals 55,861,278 voting rights. No financial instruments were reported; the notification lists completion in London on 23-Oct-2025 and states no additional information.
Positive
- Holding increased from 8.40% to 11.32% on 23-Oct-2025
- Resulting stake equals 55,861,278 voting rights
Negative
- Single holder now holds 11.32% of voting rights as of 23-Oct-2025
News Market Reaction 1 Alert
On the day this news was published, GENFF declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
LONDON, UK / ACCESS Newswire / October 24, 2025 / TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BP2C3V08 |
Issuer Name
GENFLOW BIOSCIENCES PLC |
UK or Non-UK Issuer
UK |
2. Reason for Notification
An acquisition or disposal of voting rights |
3. Details of person subject to the notification obligation
Name
Jonathan Mark Swann |
City of registered office (if applicable)
rickmansworth |
Country of registered office (if applicable)
United Kingdom |
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above
City of registered office (if applicable)
Country of registered office (if applicable)
5. Date on which the threshold was crossed or reached
23-Oct-2025 |
6. Date on which Issuer notified
23-Oct-2025 |
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer | |
Resulting situation on the date on which threshold was crossed or reached | 11.320000 | 0.000000 | 11.320000 | 55861278 |
Position of previous notification (if applicable) | 8.400000 | 0.000000 | 8.400000 | 36588550 |
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |
GB00BP2C3V08 | 55861278 | 0 | 11.320000 | 0.000000 |
Sub Total 8.A | 55861278 | |||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
Sub Total 8.B1 | ||||
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |
Sub Total 8.B2 | |||||
9. Information in relation to the person subject to the notification obligation
1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. |
Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
NONE |
12. Date of Completion
23-Oct-2025 |
13. Place Of Completion
London |
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
Who increased their stake in Genflow Biosciences (GENFF) on 23-Oct-2025?
What voting rights does Jonathan Mark Swann hold in GENFF after the 23-Oct-2025 notification?
How much did the GENFF holding change from the prior notification?
Were any financial instruments reported in the GENFF 23-Oct-2025 disclosure?
When and where was the GENFF major-holdings notification completed?
